SK Biopharmaceuticals Co (XKRX:326030) Change In Receivables : ₩-55,184 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is SK Biopharmaceuticals Co Change In Receivables?

SK Biopharmaceuticals Co's change in receivables for the quarter that ended in Mar. 2024 was ₩103 Mil. It means SK Biopharmaceuticals Co's Accounts Receivable declined by ₩103 Mil from Dec. 2023 to Mar. 2024 .

SK Biopharmaceuticals Co's change in receivables for the fiscal year that ended in Dec. 2023 was ₩-53,577 Mil. It means SK Biopharmaceuticals Co's Accounts Receivable increased by ₩53,577 Mil from Dec. 2022 to Dec. 2023 .

SK Biopharmaceuticals Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ₩119,528 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. SK Biopharmaceuticals Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 95.70.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. SK Biopharmaceuticals Co's liquidation value for the three months ended in Mar. 2024 was ₩-16,092 Mil.

SK Biopharmaceuticals Co Change In Receivables Historical Data

The historical data trend for SK Biopharmaceuticals Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Biopharmaceuticals Co Change In Receivables Chart

SK Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-110.79

-11,241.26

-38,187.48

-12,387.85

-53,577.33

SK Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															1,710.22	-11,610.40	-12,358.21	-31,318.94	103.22

SK Biopharmaceuticals Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-55,184 Mil.

SK Biopharmaceuticals Co (XKRX:326030) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

SK Biopharmaceuticals Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	119528.317	/	113974.705	*	91
=	95.70

2. In Ben Graham's calculation of liquidation value, SK Biopharmaceuticals Co's accounts receivable are only considered to be worth 75% of book value:

SK Biopharmaceuticals Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	291048.514	-	451424.683	+	0.75 * 119528.317	+	0.5 * 109276.105
=	-16,092

SK Biopharmaceuticals Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of SK Biopharmaceuticals Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Biopharmaceuticals Co (XKRX:326030) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Biopharmaceuticals Co Ltd (XKRX:326030) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

221, Pangyoyeok-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbp.com

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

SK Biopharmaceuticals Co (XKRX:326030) Headlines

No Headlines